News & Updates

Show Multimedia Only

Ipilimumab plus nivolumab elicits response in mCRPC

02 Jan 2025 by

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).

Ipilimumab plus nivolumab elicits response in mCRPC

02 Jan 2025

Expanding HPV vaccines to mid-adults: Is it worth the shot?

01 Jan 2025

Vaccination against human papillomavirus (HPV) among adults aged 27–45 years (mid-adults) is less cost-effective and generates a greater number needed to vaccinate (NNV) when compared with vaccination of persons aged 26 years and below, reports a study.

Expanding HPV vaccines to mid-adults: Is it worth the shot?

01 Jan 2025

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

30 Dec 2024 by

For Asian patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC), subcutaneous (SC) delivery of amivantamab plus lazertinib does not alter the drug’s pharmacokinetic and efficacy profile compared with the intravenous (IV) approach and is associated with fewer infusion-related reactions, according to a subgroup analysis of the phase III PALOMA-3 trial.

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

30 Dec 2024

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

27 Dec 2024 by

The combination of rezvilutamide plus androgen-deprivation therapy (ADT) proves to be efficacious and well-tolerated in the treatment of patients with high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) across all age groups, according to a post hoc analysis of the phase III CHART trial.

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

27 Dec 2024

Mitapivat cuts transfusion burden in TD thalassaemia

27 Dec 2024 by

In adults with transfusion-dependent (TD*) α- or β-thalassaemia, mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase, significantly reduces transfusion burden, with durable responses up to 36 weeks, findings from the phase III ENERGIZE-T study have shown.

Mitapivat cuts transfusion burden in TD thalassaemia

27 Dec 2024

New UC guideline endorses early use of advanced therapies

27 Dec 2024 by

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

27 Dec 2024

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024 by

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Therapeutic vaccination with ChAdOx1-HBV/MVA-HBV (VTP-300) has generated CD4+ and CD8+ cells and reduced HBsAg in a subset of chronic hepatitis B (CHB) patients with baseline values <100 IU/ml, as shown in a phase Ib/IIa trial. Moreover, a significant decrease in surface antigen occurs when the vaccine is combined with low-dose nivolumab.

Novel vaccine passes phase II trial in virally suppressed CHB

26 Dec 2024

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024 by

In the final 2-year analysis of the EBMT-SAAWP* RACE** study, the addition of eltrombopag to standard immunosuppressive treatment (IST) comprising horse antithymocyte globulin (hATG) plus cyclosporin A (CsA) improves long-term outcomes as frontline therapy for severe aplastic anaemia/very severe aplastic anaemia (SAA/vSAA).

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

26 Dec 2024

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

Treatment with proton pump inhibitors (PPIs) may contribute to a higher incidence of intestinal Behçet Disease (BD) in patients with BD, suggest the results of a study.

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Ipilimumab plus nivolumab elicits response in mCRPC

Ipilimumab plus nivolumab elicits response in mCRPC

Expanding HPV vaccines to mid-adults: Is it worth the shot?

Expanding HPV vaccines to mid-adults: Is it worth the shot?

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

PALOMA-3: Subcutaneous amivantamab makes the grade in Asians with EGFR+ NSCLC

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

Rezvilutamide + ADT delivers improved outcomes for mHSPC patients regardless of age

Mitapivat cuts transfusion burden in TD thalassaemia

Mitapivat cuts transfusion burden in TD thalassaemia

New UC guideline endorses early use of advanced therapies

New UC guideline endorses early use of advanced therapies

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

Novel vaccine passes phase II trial in virally suppressed CHB

Novel vaccine passes phase II trial in virally suppressed CHB

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

Add-on eltrombopag RACEs to the frontline for aplastic anaemia treatment

PPI use raises risk of intestinal Behçet disease

PPI use raises risk of intestinal Behçet disease